- Bupa Platinum consultant
- Fee assured
- Verified account
- Open Referral network
Specialises in
- Urology
Offers
- Face-to-face consultations
- Video and telephone consultations
About me
Dr Milan Anjanappa serves as a consultant clinical oncologist at Mount Vernon Cancer Centre in London, where he is an integral member of the uro-oncology group. He earned his primary medical qualification in India, subsequently gaining valuable experience as a clinical fellow at the esteemed Christie Hospital in Manchester before commencing his current role at Mount Vernon in 2021.
Dr Anjanappa is dedicated to a collaborative, multidisciplinary approach to patient care. He works closely alongside a highly skilled team of surgeons, expert radiologists, and fellow oncology professionals to deliver evidence-based treatments tailored to each patient's needs. Central to his ethos is the principle of shared decision-making, ensuring that patients are actively involved in their treatment choices. He places equal value on clinical outcomes and quality of life, striving to achieve the best possible results for those under his care.
As a clinical oncologist, Dr Anjanappa provides comprehensive cancer management services, encompassing radiotherapy as well as systemic anti-cancer therapies such as chemotherapy, immunotherapy, and hormonal treatment. His specialist expertise is in the management of prostate cancer, where he offers advanced modalities including Image-Guided Radiotherapy (IGRT), Stereotactic Ablative Body Radiotherapy (SABR/SBRT) delivered over five days using MR-LINAC technology, seed brachytherapy, and high dose rate brachytherapy. Additionally, he administers Lutetium PSMA therapy for patients with advanced metastatic prostate cancer.
Dr Anjanappa's expertise further extends to the management of bladder cancer, with a focus on bladder-preserving strategies utilising radiotherapy. He provides SABR/SBRT for renal malignancies (kidney cancers) and metastatic disease as well.
He is actively involved in research, regularly enrolling patients into national and international clinical trials to advance the field of oncology. Committed to professional development and knowledge sharing, Dr Anjanappa has delivered presentations at various national societies and has contributed papers at prominent conferences, reflecting his ongoing commitment to both clinical excellence and academic advancement.
Areas of interest
Prostate cancer; seed brachytherapy; Lutetium-177 PSMA therapy; HDR brachytherapy; SABR/SBRT; MR Linac; Kidney SABR/SBRT; radiotherapy; IMRT/IGRT; chemotherapy; hormone therapy; immunotherapy; bladder cancer; Oligo-metastasis SABR/SBRT
Medical secretaries
- Amy Bignell
- Mount Vernon Cancer Centre Rickmansworth Road Northwood Middlesex HA6 3NN
- 020 3826 2182
- abignell@macancerclinic.co.uk
Information for healthcare professionals (Bupa patients only, last 12 months)
-
X0004
Clinical supervision and planning for the delivery of chemotherapy and/or systemic anti-cancer therapy for 1-28 days - (5-50)
Mount Vernon Cancer Centre (5-50) Bishops Wood Hospital (1-5)
-
X0008
Clinical supervision of external beam radiotherapy, for 16 or up to and including 30 fractions - (1-5)
-
X6772
Preparation for complex radiotherapy with Intensity Modulated Radiotherapy (IMRT) - (1-5)
-
H4685
Insertion of biodegradable perirectal spacer under image guidance - (1-5)